Abstract
Because novel SARS-CoV-2 variants continue to emerge, immunogenicity of XBB.1.5 monovalent vaccines against live clinical isolates needs to be evaluated. We report boosting of IgG (2.1×), IgA (1.5×), and total IgG/A/M (1.7×) targeting the spike receptor-binding domain and neutralizing titers against WA1 (2.2×), XBB.1.5 (7.4×), EG.5.1 (10.5×), and JN.1 (4.7×) variants.
Keywords:
COVID-19; SARS; SARS-CoV-2; United States; allergy and immunology; antibodies; coronavirus; coronavirus disease; respiratory infections; severe acute respiratory syndrome coronavirus 2; vaccines; viruses.
MeSH terms
-
Adult
-
Antibodies, Neutralizing* / blood
-
Antibodies, Neutralizing* / immunology
-
Antibodies, Viral* / blood
-
Antibodies, Viral* / immunology
-
COVID-19 Vaccines* / administration & dosage
-
COVID-19 Vaccines* / immunology
-
COVID-19* / immunology
-
COVID-19* / prevention & control
-
Female
-
Humans
-
Immunity, Humoral*
-
Immunogenicity, Vaccine
-
Immunoglobulin A / blood
-
Immunoglobulin A / immunology
-
Immunoglobulin G / blood
-
Immunoglobulin G / immunology
-
SARS-CoV-2* / immunology
-
Spike Glycoprotein, Coronavirus* / immunology
Substances
-
COVID-19 Vaccines
-
Antibodies, Viral
-
Antibodies, Neutralizing
-
Spike Glycoprotein, Coronavirus
-
Immunoglobulin G
-
Immunoglobulin A
-
spike protein, SARS-CoV-2